Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults by Arham Ali et al.
Ali et al. Critical Care  (2015) 19:217 
DOI 10.1186/s13054-015-0913-xRESEARCH Open AccessPropranolol attenuates hemorrhage and
accelerates wound healing in severely
burned adults
Arham Ali1,2, David N Herndon1,2, Ashish Mamachen3, Samir Hasan3, Clark R Andersen2, Ro-Jon Grogans1,2,
Jordan L Brewer3, Jong O Lee1,2, Jamie Heffernan1, Oscar E Suman1,2 and Celeste C Finnerty1,2,4*Abstract
Introduction: Propranolol, a nonselective β-blocker, exerts an indirect effect on the vasculature by leaving
α-adrenergic receptors unopposed, resulting in peripheral vasoconstriction. We have previously shown that
propranolol diminishes peripheral blood following burn injury by increasing vascular resistance. The purpose of this
study was to investigate whether wound healing and perioperative hemodynamics are affected by propranolol
administration in severely burned adults.
Methods: Sixty-nine adult patients with burns covering ≥30% of the total body surface area (TBSA) were enrolled
in this IRB-approved study. Patients received standard burn care with (n = 35) or without (control, n = 34) propranolol.
Propranolol was administered within 48 hours of burns and given throughout hospital discharge to decrease heart rate
by approximately 20% from admission levels. Wound healing was determined by comparing the time between grafting
procedures. Blood loss was determined by comparing pre- and postoperative hematocrit while factoring in operative
graft area. Data were collected between first admission and first discharge.
Results: Demographics, burn size, and mortality were comparable in the control and propranolol groups. Patients in
the propranolol group received an average propranolol dose of 3.3 ± 3.0 mg/kg/day. Daily average heart rate over
the first 30 days was significantly lower in the propranolol group (P <0.05). The average number of days between
skin grafting procedures was also lower in propranolol patients (10 ± 5 days) than in control patients (17 ± 12 days;
P = 0.02), indicative of a faster donor site healing time in the propranolol group. Packed red blood cell infusion was
similar between groups (control 5.3 ± 5.4 units vs. propranolol 4.4 ± 3.1 units, P = 0.89). Propranolol was associated
with a 5 to 7% improvement in perioperative hematocrit during grafting procedures of 4,000 to 16,000 cm2 compared
to control (P = 0.002).
Conclusions: Administration of propranolol during the acute hospitalization period diminishes blood loss during skin
grafting procedures and markedly improves wound healing in severely burned adults. As burn patients require serial
surgical interventions for motor and cosmetic repair, restricting blood loss during operative intervention is optimal.Introduction
A severe burn injury is characterized by a profound in-
crease in metabolism, far beyond that produced by other
forms of trauma. Hypermetabolism is mediated by a
surge in stress hormones including catecholamines [1,2]
and glucocorticoids and may persist long after the initial* Correspondence: ccfinner@utmb.edu
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unless otherwise stated.burn insult [3,4]. Cardiac stress following burn injury is
characterized by increased cardiac work, cardiac output,
resting heart rate, rate pressure product, and stroke
volume. If left untreated, these perturbations in cardiac
physiology contribute greatly toward postburn morbidity
and mortality.
Hyperdynamic changes to the cardiovascular system are
frequently associated with copious amounts of operative
blood loss. Paired with inadequate resuscitative efforts and
shifts in fluid compartments, these changes cause many
patients with burn injury to become hemodynamicallyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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serial skin grafting procedures, limiting hemorrhage during
these operations becomes paramount to early recovery.
Propranolol, a nonselective β-blocker, has widespread
systemic effects following burn injury. Recently, we re-
ported that administration of propranolol in children
with severe burn injury for one year significantly improves
body composition, resting energy expenditure, and cardiac
function [5]. Attenuation of cardiac sequelae occurred in a
dose-dependent manner with the most favorable results
noted at a dose of 4 mg/kg/day [6]. Peripherally, pro-
pranolol decreases lower limb blood flow by increasing leg
vascular resistance in severely burned adults [7]. Induction
of peripheral vasoconstriction by propranolol has led
to the successful implementation of the β-blocker in
the management of infantile hemangiomas, [8,9] variceal
bleeding, [10] and recurrent epistaxis [11]. An overview of
the mechanisms by which propranolol induces peripheral
vasoconstriction is presented in Figure 1. Whether or not
the effects of these changes on cardiovascular function
alter operative hemorrhage or wound healing times re-
mains to be determined. Here we report the perioperative
effects of propranolol administration in adults with severe
burn injury in a prospective, single-institution study.
Materials and methods
Patient enrollment and stratification
One thousand seven hundred four patients were admit-
ted or referred to the Blocker Burn Unit at the Univer-
sity of Texas Medical Branch between November 2004Figure 1 Proposed mechanism by which propranolol induces peripheral v
can be attributed to three main actions. (1) Inhibition of β1 receptors in the
vasoconstriction via stimulation of α1 receptors in vascular smooth muscle.
(3) By blocking β-adrenergic effects of circulating catecholamines epinephrine
resulting in vascular smooth muscle contraction. Solid arrows indicate direct eand 1 January 2014. One thousand six hundred thirty-
one patients did not meet the following inclusion cri-
teria: older than 18 years, burn wounds covering ≥30%
of the total body surface area (TBSA), treatment with at
least one surgical skin grafting procedure, and consent
to participate in data collection (Figure 2). All patients
meeting the inclusion criteria provided freely tendered
consent to participate in the study, which was approved
by the Institutional Review Board of the University of
Texas Medical Branch (Galveston, TX). The treatment
protocols were stable during the study period, as deter-
mined by stability in the length of hospital stay (LOS)
(0.5 days per percent TBSA burned), morbidity (infec-
tions, lung injury, and acute kidney injury), and mortal-
ity. Four patients randomized to the propranolol group
never received propranolol and were excluded from the
study. The data presented here were collected from 69
adult patients with burns who received standard of care
established at our hospital and described in detail pre-
viously [12,13]. Within 48 hours of hospital admission,
patients received either standard burn care treatment
(control; n = 34) or standard burn care treatment plus
propranolol (propranolol; n = 35), which was administered
throughout hospitalization to decrease baseline heart rates
by approximately 20%. Target dosing was achieved as pre-
viously described [5]. If bradycardia occurred, the fol-
lowing dose of propranolol was withheld. Propranolol
administration was re-initiated after 16 hours beginning at
one half of the original dose. Thereafter, the dose was ti-
trated back to target levels over the following 48 hours.asoconstriction. Induction of peripheral vasoconstriction by propranolol
heart decreases cardiac output, thereby inducing reflexive peripheral
(2) Direct inhibition of β2 receptors incites peripheral vasoconstriction.
and norepinephrine, α1-adrenergic receptor effects remain unopposed,
ffects, and broken arrows indicate indirect effects.
Figure 2 Patient enrollment diagram.
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Over the first 24 hours following admission, resuscita-
tion was accomplished per the Parkland formula (4 ml ×
weight (kg) × TBSA burned (%)) with lactated Ringer’s
solution given incrementally [14]. Hypovolemia was
treated with crystalloid or colloid fluids based on the
individual clinician’s preference. Vasotropes or inotropes
were used when patients did not respond to volume in-
fusion or if the patient was in septic shock. Total burn
wound excision was performed on all patients within 48
hours of admission. Autograft and homograft skin were
used to cover the wounds. Grafting procedures were re-
peated once the donor site wounds healed (approximately
once a week). Therefore, the time in between grafting
procedures indicated approximate wound healing times.
Patients were discharged once wounds were deemed to be95% healed. An outline of the course of surgical interven-
tions from the time of burn injury to the time of discharge
is provided in Figure 3.
Nutrition was provided by continuous nasoduodenal
tube feeds in the form of Vivonex total enteral nutrition
(composition: 82% carbohydrate, 15% protein, and 6% fat)
(Nestle HealthCare Nutrition, Inc., MN, USA). Nutrition
and metabolism were monitored by assessing serum levels
of albumin, transthyretin, and retinol-binding protein.
Weight and urinary output were measured daily.
Perioperative blood loss
Blood loss was estimated visually by the surgical and
anesthesiology teams as described in surgical literature
[15,16]. Perioperative hematocrit levels were defined as
values obtained within 12 hours before or after skin
Figure 3 Patient enrollment and timeline of hospital course. Patients were admitted within 7 days of burn injury. Over the next 48 hours, patients
were randomized to control (n = 34) or propranolol (n = 35) groups and then underwent total burn wound excision. Thereafter, patients underwent
serial skin grafting procedures once donor sites wounds healed. Patients were then discharged once wounds were deemed to be 95% healed.







Age, yr 38 ± 16 41 ± 14 0.33
Sex, males (%) 30 (88) 29 (83) 0.73
Burn type, n (%)
Electrical 1 (3) 2 (6) 0.96
Flame 30 (88) 30 (86)
Other 3 (9) 3 (8)
TBSA burn,% 59 ± 22 49 ± 18 0.04
TBSA third,% 45 ± 29 40 ± 22 0.48
Burn to admission, d 1 ± 1 1 ± 3 0.36
LOS (survivors), d 52 ± 54 46 ± 35 0.99
LOS (nonsurvivors), d 30 ± 34 20 ± 9 0.50
LOS/TBSA, d 0.8 ± 0.8 0.9 ± 0.6 0.30
Mortality, n (%) 10 (29) 6 (17) 0.36
Data are presented as mean ± standard deviation or count (percentage). LOS,
length of stay; TBSA, total body surface area.
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hematocrit values obtained closest to the time of operative
intervention were used. Patients lacking corresponding
hematocrit values within this time frame were omitted.
Statistical methods
Data with normal distribution were analyzed using an
unpaired Student’s t test and Fisher’s exact test. Data
with unequal or skewed distribution were either trans-
formed or analyzed using Mann-Whitney rank-sum
tests. Patient demographic and burn injury characteristic
data were described as mean ± standard deviation or
counts (percentages) where appropriate. Propranolol dos-
ing, daily heart rates, wound healing, skin grafting pro-
cedure, and blood loss data were described as mean ±
standard deviation unless otherwise noted.
The relationship between change in preoperative and
postoperative hematocrit levels and skin graft area was
modeled by linear regression to a quadratic curve and
included an interaction between treatment group (con-
trol vs. propranolol) and skin graft area. Skin graft area
was log transformed for improved centering. A likeli-
hood ratio test was used to assess the significance of
treatment effect. Change in hematocrit vs. skin graft area
was described as adjusted means ± 95% confidence in-
tervals. Statistical analysis was performed using R statis-
tical software (R Core Team, 2013, version 3.1.1). A 95%
level of confidence was assumed.
Results
Patient disposition and burn injury characteristics
Sixty-nine patients with ≥30% TBSA burns were evalu-
ated; 34 adult burn patients were randomized to the con-
trol cohort, and 35 adult burn patients were randomizedto the propranolol cohort. Age, sex, etiology of burn in-
jury, burn to admission time, and duration of acute
hospitalization were similar between cohorts (Table 1). Al-
though TBSA burned was higher in control patients than
in propranolol patients (59 ± 22% vs. 49 ± 18%; P = 0.04),
the percent of full-thickness burns was similar between
groups (control 45 ± 29% vs. propranolol 40 ± 22%;
P = 0.48), indicating similar burn severity.
Propranolol dosing
Patients in the propranolol group received an average
dose of 3.3 ± 3.0 mg/kg/day for an average of 40 ± 40
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postburn.
Cardiac function
Daily mean heart rate was significantly decreased in pa-
tients receiving propranolol compared to control (Figure 4;
P <0.05). Heart rates between postburn days 2 to 30 in
propranolol patients were, on average, 11 ± 4 beats per
minute lower than those in the control group. Control
patients remained tachycardic (>100 beats/min) through-
out hospitalization. Conversely, normal heart rates were
achieved in the propranolol group by postburn day 7, with
a relatively sustained decrease in heart rate by postburn
day 12.
Wound healing
The average number of skin grafting procedures each
patient underwent was the same for each group (4 ± 3
procedures; P = 0.90; Table 2). However, the time between
skin grafting procedures was lower in the propranolol co-
hort than in the control cohort (10 ± 5 days vs. 17 ± 12
days; P = 0.02). These data indicate that propranolol sig-
nificantly improves donor site wound healing time by an
average time of one week compared to the control treat-
ment. Graft type was not different between groups (data
not shown).
Blood loss during skin grafting procedures
Patients in the propranolol group underwent significantly
larger skin grafting procedures (propranolol 4,500 ± 4,000
cm2 vs. control 3,300 ± 4,800 cm2; P = 0.01), yet required
a similar number of packed red blood cell (PRBC) trans-
fusions as the control group to maintain perioperative
hematocrit levels (propranolol 4.4 ± 3.1 units vs. control
5.3 ± 5.4 units; P = 0.89). Average blood loss (estimated)Figure 4 Daily heart rate. Daily mean heart rate was significantly lower in p
mean ± standard error of the mean. *P <0.05.was similar between groups (control 0.37 ± 0.73 ml/cm2
excised vs. propranolol 0.26 ± 0.21 ml/cm2 excised;
P = 0.70; Table 2).
The relationship between skin graft area and change in
perioperative hematocrit levels indicated that, as skin
graft area increased, patients in the control cohort exhib-
ited a significant decrease in perioperative hematocrit. In
contrast, with increased skin graft area, patients on pro-
pranolol significantly maintained perioperative hematocrit
levels (P = 0.002). A graft size of 4,000 cm2 was associated
with a 5.2% improvement in perioperative hematocrit in
the propranolol group over the control group (P = 0.002;
Figure 5).
As expected, a correlation existed between mortality
and graft size in all adults with burn injury, irrespective
of treatment group. A significant difference was noted in
both mean graft area per skin grafting procedure and in
the sum of the areas used for all skin grafting procedures
(Table 3).
Fluid balance and acid base control
Net fluid balance was compared at 24, 48, and 72 hours
post-admission. Twenty-four hours following hospital
admission, net fluid balance was 11,100 ± 10,200 ml in
the control cohort and 6,100 ± 5,800 ml in the propran-
olol cohort (P = 0.06). At 48 hours post-admission, net
fluid balance was 6,500 ± 5,700 ml in the control cohort
and 6,300 ± 7,500 ml in the propranolol cohort (P = 0.46).
Finally, at 72 hours post-admission, net fluid balance was
3,900 ± 5,200 ml in the control cohort and 1,800 ± 2,800
ml in the propranolol cohort (P = 0.09). As these values
did not significantly differ between groups, we cannot
attribute hypotension to hypovolemia. Similarly, no sig-
nificant difference in arterial pH was noted between
groups over the first 72 hours following hospitalatients on propranolol than in control patients. Data are presented as
Table 2 Wound healing and skin grafting procedures
Parameter Control Propranolol p Value
Wound healing
Number of SGP/patient 4 ± 3 4 ± 3 0.90
Duration between SGP (days) 17 ± 12 10 ± 5 0.02
Skin grafting procedures
Skin graft area (cm2) 3,300 ± 4,800 4,500 ± 4,000 0.01
Preoperative HCT (%) 32 ± 9 30 ± 8 0.05
Postoperative HCT (%) 28 ± 6 28 ± 5 0.24
PRBC transfused (units) 5.3 ± 5.4 4.4 ± 3.1 0.89
EBL/graft area (ml/cm2) 0.37 ± 0.73 0.26 ± 0.21 0.70
Data presented as mean ± standard deviation. EBL, estimated blood loss; HCT,
hematocrit; PRBC, packed red blood cells; SGP, skin grafting procedures.






Mean graft area, cm2 3,440 ± 3,670 7,910 ± 3,420 0.002
Total graft area, cm2 9,960 ± 1,1150 20,170 ± 1,1340 0.01
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pH was 7.23 ± 0.13 in control patients and 7.28 ± 0.08
in propranolol-treated patients (P = 0.08). At 48 hours
post-admission, the pH was 7.32 ± 0.09 in control pa-
tients and 7.32 ± 0.10 in propranolol-treated patients
(P = 0.85). Finally, 72 hours post-admission, the pH
was 7.34 ± 0.15 in control patients and 7.39 ± 0.06 in
propranolol-treated patients (P = 0.43). There were no sig-
nificant differences between groups.
Adverse events
Incidents of the following adverse events were recorded
for patients in both groups: bradycardia (<60 beats/min),Figure 5 Propranolol significantly stabilizes perioperative hematocrit
levels. Patients receiving propranolol maintained perioperative
hematocrit levels compared to control patients. Propranolol was
associated with a 1.6% improvement in perioperative hematocrit
levels during grafting procedures with a graft area of 100 cm2, 2.5%
improvement with 300 cm2, 3.6% improvement with 1,000 cm2,
5.2% improvement with 4,000 cm2, and 7.1% improvement with
16,000 cm2 (P = 0.002). Data are presented as adjusted mean ± 95%
confidence intervals (shaded).bradypnea (<12 breaths/min), hypotension (systolic <90
mm Hg, diastolic <60 mm Hg), and ischemia (mean
arterial pressure <60 mm Hg). Adverse event incidence
was comparable in each group. There were no signifi-
cant differences between groups (Table 4).
Discussion
One of the most significant contributors to decreased
morbidity and mortality following severe burn injury has
been the advent of early operative burn wound excision
executed within the first 48 hours following burn injury
[17-19]. Delayed excision has been associated with in-
creased wound contamination, graft loss, hospital stay,
hemorrhage, sepsis, and death [17-20]. Although early ex-
cision is associated with decreased hemorrhage, patients
with severe burn injury often require multiple skin graft-
ing procedures. Consequently, operative intervention is
often required when intraoperative hemorrhage is at a
peak, during 2 to 16 days postburn [17]. Therefore, phar-
macotherapeutics that decrease intraoperative hemorrhage
may augment hemodynamic recovery following surgical
intervention in patients with burn injury.
In this prospective study, we investigated the effects of
propranolol on the cardiovascular system and wound
healing in 69 adults with severe burn injury. Demographic
and burn injury characteristics did not differ between
groups except with regard to TBSA burned. As patients inTable 4 Adverse events
Group n (%) P value
Bradycardia
Control 3 (9) 0.47
Propranolol 6 (17)
Bradypnea
Control 13 (38) 0.63
Propranolol 16 (46)
Hypotension
Control 14 (41) 1.00
Propranolol 14 (40)
Ischemia
Control 13 (38) 0.23
Propranolol 19 (54)
Bradycardia, pulse <60 bpm; bradypnea, respiratory rate <12 breaths/minute;
hypotension, systolic/diastolic blood pressure <90/60 mm Hg; ischemia, mean
arterial pressure <60 mm Hg.
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greater percentages of the TBSA, it is expected that these
patients would exhibit more operative blood loss during
burn excision. However, we have previously shown that,
during primary burn excision in children, the area of
TBSA burned is not a significant determinant of blood
loss. Rather, the area of devitalized tissue excised contrib-
utes to approximately 50% of the variability in blood loss
during skin grafting procedures. Furthermore, the extent
of full-thickness burn injury is associated with significantly
more blood loss as well [21]. Therefore, the implementa-
tion of a bias due to the significant difference in TBSA
burned between groups in this study was not of con-
cern as both groups experienced a similar severity of
full-thickness burn (control 45 ± 29% vs. propranolol
40 ± 22%; P = 0.48).
Propranolol significantly reduced the time between
grafting surgeries by one week, on average. This data is
consistent with results from a study of 79 Iranian pa-
tients with moderate burn injury (approximately 30%
TBSA burns) in which propranolol improved healing
times of both partial and full-thickness burns [22]. How-
ever, it should be noted that the investigators of the
aforementioned study excised burn wounds according to
a delayed approach, approximately one month after ini-
tial burn injury.
β-adrenergic receptors are found widely in cutaneous
fibroblasts, keratinocytes, and endothelial cells. Pullar
and colleagues reviewed the effects of β2-adrenergic
receptor modulation on wound repair and reported
modulatory effects on cell proliferation and migration
via galvanotaxis, inflammation via neutrophil chemotaxis,
wound contraction and re-epithelialization via keratino-
cyte migration and fibroblast mediation, and angiogenesis
via cyclic AMP-mediated vascular endothelial-derived
growth factor expression [23]. In fact, β2-adrenergic
receptor inhibition in a murine model resulted in in-
creased dermal fibroblast function and re-epithelialization
during the early stages of wound repair [24]. Alterations
in microvascular blood flow induced by β-blockade may
play a role in wound healing as well. In a rodent model,
low (2 mg/kg) and high (20 mg/kg) doses of propranolol
resulted in 35% lower cortical regional cerebral blood flow
than the control treatment. Additionally, propranolol
significantly reduced mean oxygen consumption with-
out effecting oxygen saturation levels compared to the
control treatment [25]. Regarding coagulation, propranolol
abolished isoproterenol-induced increases in plasma von
Willebrand factor antigen levels but had no effect on tissue
factor or D-dimer expression in hypertensive patients.
These data suggest that propranolol may protect against
endothelial cell damage, as increased von Willebrand factor
levels are indicative of vascular injury [26]. Here we re-
port significantly faster donor site wound healing timesin patients receiving propranolol following burn injury.
Ongoing studies of the samples from these patients will
allow for elucidation of the molecular effects of propran-
olol that underlie improved healing after burn injury.
On average, patients in the propranolol cohort under-
went operative procedures with graft areas 1,200 cm2
larger than those in the control group. The goals of early
excision of the burn wound include the removal of all
devitalized and necrotic tissue, which if left untreated,
would provoke bacterial contamination and impede ad-
equate wound healing. More often than not, an accurate
assessment of partial thickness and full-thickness burns
cannot be obtained until patients undergo operative
intervention. Burn patients are assessed on a case-by-
case basis with final evaluation of skin graft area being
decided within the operating theater. Error in primary
clinical assessment of viable and nonviable tissue likely
explains the difference in final graft area required. As es-
timated blood loss is often an inaccurate and subjective
assessment of hemorrhage, we decided to measure blood
loss using an objective approach. Perioperative hematocrit
levels were plotted against skin graft area, accounting for
severity of injury and surgical intervention for each pa-
tient. We found that propranolol administration was asso-
ciated with a 5% improvement in perioperative hematocrit
levels during skin grafting procedures of 4,000 cm2. More-
over, the attenuation of blood loss was even more pro-
found after larger skin grafting procedures. These findings
may be attributed to the various effects of propranolol on
the cardiovascular system.
Direct inhibition of β-adrenergic receptors in the heart
decreases heart rate, blood flow, and cardiac output.
Angiogenesis may be attenuated via vasoconstriction,
and decreased expression of matrix metalloproteinases,
basic fibroblast growth factor, and vascular endothelial
growth factor may limit operative hemorrhage with pro-
pranolol administration. Similarly, propranolol enhances
upregulation of capillary endothelial cells and apoptosis,
further limiting angiogenesis and blood loss [11,27]. Fi-
nally, earlier work by our group has provided evidence
that propranolol administration significantly reduces per-
ipheral perfusion via increased leg vascular resistance in
adults with severe burn injury [7]. However, in this work,
we observed a reduction in arterial and venous lactate
levels in both nonburned and burned adults following
two hours of intravenous propranolol administration.
β-blockade was thought to have reduced lactate produc-
tion via inhibition of lipolysis [7]. In the current study, we
found no difference in arterial pH between groups over
the first 72 hours following hospital admission. Therefore,
decreased chronotropic effects during early resuscitation
in patients treated with propranolol did enhance acidosis
further than expected by the nature of severe burn injury,
as evidenced in the control group.
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fluids have long been a subject of debate. One of the limi-
tations of the current study was the omission of com-
prehensive resuscitation data in our analysis. However,
administration of PRBC is likely the strongest contributor
to altered perioperative hematocrit levels in adults with
burn injury. As no difference in PRBC administration was
noted between groups and target hemoglobin levels re-
mained constant among groups, we are confident that
resuscitation with various other colloid and crystalloid
products follow a similar pattern.
Finally, it bears mentioning that the findings from our
study may not be limited to burn injury. For example,
propranolol may attenuate hemorrhage perioperatively
in patients on anticoagulant therapy requiring emergency
surgical intervention. Alternatively, propranolol may im-
prove wound healing times after bedside or surgical de-
bridement for various diseases. The effect of propranolol
on wound healing and hemorrhage in other injury/disease
models deserves further investigation.Conclusions
In severely burned adults, administration of propranolol
during acute hospitalization diminishes blood loss during
skin grafting procedures and speeds wound healing.Key messages
 Propranolol, given throughout hospitalization at a
dose that reduces admission heart rate by 20%,
speeds wound healing by one week, on average.
 Propranolol administration also diminishes blood
loss, as assessed by perioperative hematocrit levels.
This effect becomes more profound as skin graft
area increases.Abbreviations
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